^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | c-MET inhibitor + Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
3683 / 13 - MET exon 14 skipping mutations in lung cancer: Screening, functional and clinical impact
Published date:
05/27/2020
Excerpt:
This panel revealed METex14 alterations in 2.2% NSCLC patients and presence of various concurrent alterations. Third, by further characterization of the concurrent alterations, we found high rate of PI3K pathway alterations in METex14 patients. In addition, MET-TKI treatment in 3 patients harboring these alterations had shown progressive disease, suggesting their involvement in resistance.
